Member Info for CTSFO

P1a is different for oncology. Here the patients mostly aren’t fit and healthy. We know the trials are being performed on patients with a very limited life expectancy.

“ Imagine a scenario that without a new injection of cash, AVCT struggles to fund the development and clinical trials of its cutting edge, platform technology”

I’m imagining this sentence with correct punctuation.

Good point PL75. I’ll take the AVA6000 please, upping the dose of plain dox is going to fry peoples nerves.

https://link.springer.com/article/10.1007/s12640-023-00652-5

Please don’t take this as FUD. Something to be aware of. A small molecule drug is undergoing clinical trials to see if it reduces / stops the cardiotoxicity of doxorubicin. No mention of it reducing the bone marrow suppression effects of doxorubicin. Important we know about this. Though it will potentially allow higher doses of doxorubicin, they won’t be targeted directly into the TME. And AVA6000 is just one of many prodrugs that will be developed off the platform.

https://www.cancer.gov/news-events/cancer-currents-blog/2020/doxorubicin-target-bax-prevent-heart-damage

Time to fight back:

https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcTCYmxvuUyj-xBPXh1rSz3ndot82nbBPqOVDA&usqp=CAU

Gje360, Thank you, that’s very helpful. It’s certainly been a frustrating few weeks. Hopefully it was all manipulated for yesterday, and now we’ll see a correction. GLA.

Ice, a serious and definitely not FUD answer. We know Avacta are having serious conversations with interested parties. Licensing, JV, and TO are all possibilities. If they’ve also negotiated a placing BUT at a good price per share, not a bucket shop offer, then it gives them financial resilience going forward. It de risks the business, and allows negotiation from a better position. We know Pharma research is expensive, having this buffer in place makes sense. We also know how much further along the AVA platform is since the CLN. Far far more worth in the IP now. Just a thought.

GLA, hope we’re all heading back the way we should be. 🤞🏻✊🏻

Wyn, I hope this isn’t a ‘dead cat bounce’ today. As was posted earlier, £1.00 seems to be the point around which the price oscillates at present. Possibly an overshoot and settle back to that in the coming week or so.

i think the collective noun is a ‘****ifroth’ of clowns. or something like that.

AACR site and timeline for submissions

https://www.aacr.org/meeting/aacr-annual-meeting-2024/key-dates/

I hope it’s a big, main stage, reveal of all the P1 Arm 1 data.

@BV is absolutely right we need some updates about P1A1 and P1A2. I appreciate Avacta will want to save the hard facts and data for the conference. However they are AIM Regs bound to update us about trials. Knowing all 7 cohorts have been successfully completed is price sensitive.

DaProphet… and… buy the dip!!

Did you get her number? I need all the help and advice I can get at present. And waterproof bed sheets. GLA!

An interesting comment on another platform: RUMOUR!!

A placing is coming in from a serious US investor at £1.00 a share. It’s a one off comment. But would tie in with what we’ve seen.

The failed fund manager / pizza boy / journalist… those that can do, those that can’t become share tipsters… is absolutely clueless in his pieces about Avacta. Ad nauseum comments about funding, but utterly fails to understand AVA6000 is a pro-drug. His followers are too cerebrally challenged to check what he says. So he gives them the risk profile of a brand new molecule being taken through all the phases to market. Misleading, Malign, or just plain Dunning Kruger effect?

It’s time to let him know what we think.

“Our mission is to improve patients’ lives and grow shareholder value by developing novel cancer therapies and powerful diagnostics using our proprietary Affimer® and pre|CISION™ platforms. Clear communication of our corporate objectives and keeping our shareholders up to date with progress, as well as informing potential new investors about the investment opportunity, is at the core of our communications programme. I hope you find the information you are looking for and welcome any feedback

ALASTAIR SMITH, CHIEF EXECUTIVE OFFICER”

Good luck everyone, tomorrow and the coming weeks.

Bella, I’m sorry! You’re absolutely right, it looks like blatant plagiarism. I skim read your post and didn’t think it through properly.

But

Great minds…

Best conspiracy theory…

The short has been orchestrated by the CLN provider to maximise the number of shares in the next payment… cos they know a huge deal has been agreed and they’re about to get paid off in cash in full!! Go on, beat that!!!

Livedataaccount & LLP, good points. An RNS stating “Cohort 7 now complete. Data is now being analysed with a plan to submit at AACR April 2024.” Would be a possibility?

I’ve just been through all the RNSs about attending the AACR. Avacta updates the market via an RNS late March about its plans to attend and what it will be presenting. Nothing out of the ordinary in no updates so far. Personally I want them to take as much time as possible, and incorporate as much data as they can. Presenting the completed P1 Arm1 dataset is bound to generate interest.